Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
REGN Investors with Losses Encouraged to Contact the Firm Before Mar. 10th, 2025 Deadline REGN Investors with Losses Encouraged to Contact the Firm Before Mar. 10th, 2025 Deadline
NEW YORK, NY / ACCESS Newswire / February 28, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the fede
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
12:00pm, Friday, 28'th Feb 2025
LOS ANGELES , Feb. 28, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: RE
NEW YORK, NY / ACCESS Newswire / February 28, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the fede
The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.
11:00am, Friday, 28'th Feb 2025
LOS ANGELES, CA / ACCESS Newswire / February 28, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceutical
NEW YORK, NY / ACCESS Newswire / February 28, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the fede
NEW YORK CITY, NY / ACCESS Newswire / February 28, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Re
Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma
07:00am, Friday, 28'th Feb 2025
TARRYTOWN, N.Y., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human
NEW YORK , Feb. 28, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) of a class action securities lawsuit
Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) - March 10, 2025 Deadline to Join – Contact Levi & Korsinsky
08:45pm, Thursday, 27'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the fede
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN
08:00pm, Thursday, 27'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ:R
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN
02:00pm, Thursday, 27'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the fede
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the fede
Shareholders that lost money on Regeneron Pharmaceuticals, Inc.(REGN) should contact Levi & Korsinsky about pending Class Action - REGN
12:39pm, Thursday, 27'th Feb 2025
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) of a class action securities lawsu
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) between N
